PA
TCRT icon

Prism Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Prism Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-116
Closed -$55K – 57
2018
Q2 		$55K Sell
116
-9
-7% -$5.71K 0.03% 56
2018
Q1 		$85K Buy
125
+27
+28% +$16.8K 0.05% 53
2017
Q4 		$61K Buy
+98
New +$70.4K 0.03% 53

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Prism Advisors's TCRT Position: Q3 2018 in Review

Prism Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2018, closing a stake of 116 shares — an estimated $55K sold.

Prism Advisors first reported a position in TCRT in Q4 2017 and held it in 3 quarters. The position peaked at $85K in Q1 2018. 131 funds tracked by Wall St. Rank hold TCRT as of Q3 2018.

  • Prism Advisors reported no remaining Alaunos Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Prism Advisors sold 116 Alaunos Therapeutics shares in Q3 2018, an estimated $55K.
  • Prism Advisors first reported a position in Alaunos Therapeutics in Q4 2017 and held it in 3 quarters.
  • Prism Advisors's Alaunos Therapeutics position peaked at $85K in Q1 2018.
  • 131 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2018.

Based on Prism Advisors's 13F filing for Q3 2018, filed 26 Oct 2018.